Walgreens #6616 | |
2105 E Fire Tower Rd, Greenville, North Carolina 27858 | |
(252) 321-6582 |
Name | Walgreens #6616 |
---|---|
Organization Name | Walgreen Co |
Location | 2105 E Fire Tower Rd, Greenville, North Carolina 27858 |
Type | Durable Medical Equipment & Medical Supplies Supplier |
Phone | (252) 321-6582 |
Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Lab21 Limited, the global specialist in personalized medicine and clinical diagnostics, today announces the completion of a worldwide license from Cooperative Diagnostics to use its suite of patents and expertise for the development of its growing pipeline of molecular diagnostic kits. Financial details of the agreement were not disclosed.
"The links between climate, hunger and poor nutrition are becoming increasingly clear: a recent report for the Committee on World Food Security warned that climate change could significantly change the amount and quality of food consumed - with potentially devastating consequences for those most at risk of hunger," Irish Deputy Prime Minister Eamon Gilmore; Mary Robinson, president of the Mary Robinson Foundation Climate Justice; Ertharin Cousin, executive director of the World Food Programme; and Frank Rijsberman, CEO of the CGIAR Consortium, write in the CGIAR blog.
A new barcode chip developed by a multi-institutional team of investigators promises to revolutionize diagnostic medical testing. In less than 10 minutes and using just a pinprick's worth of blood, the chip can measure the concentrations of dozens of proteins, including those that herald the presence of diseases such as cancer and heart disease.
Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.
Amplimmune, Inc. today announced that it has entered into a broad strategic alliance with GlaxoSmithKline (GSK) to further develop PD-1 targeting therapies that may be effective in the treatment of cancer and other diseases. GSK will obtain exclusive worldwide rights to AMP-224 as well as other potential next generation fusion proteins that target PD-1.
› Verified 1 days ago
NPI Number | 1336156397 |
Organization Name | WALGREEN CO |
Doing Business As | WALGREENS #06616 |
Type | Durable Medical Equipment & Medical Supplies Supplier |
Address | 2105 E Fire Tower Rd, Greenville, NC 27858 |
Phone Number | 252-321-6582 |
News Archive
Lab21 Limited, the global specialist in personalized medicine and clinical diagnostics, today announces the completion of a worldwide license from Cooperative Diagnostics to use its suite of patents and expertise for the development of its growing pipeline of molecular diagnostic kits. Financial details of the agreement were not disclosed.
"The links between climate, hunger and poor nutrition are becoming increasingly clear: a recent report for the Committee on World Food Security warned that climate change could significantly change the amount and quality of food consumed - with potentially devastating consequences for those most at risk of hunger," Irish Deputy Prime Minister Eamon Gilmore; Mary Robinson, president of the Mary Robinson Foundation Climate Justice; Ertharin Cousin, executive director of the World Food Programme; and Frank Rijsberman, CEO of the CGIAR Consortium, write in the CGIAR blog.
A new barcode chip developed by a multi-institutional team of investigators promises to revolutionize diagnostic medical testing. In less than 10 minutes and using just a pinprick's worth of blood, the chip can measure the concentrations of dozens of proteins, including those that herald the presence of diseases such as cancer and heart disease.
Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.
Amplimmune, Inc. today announced that it has entered into a broad strategic alliance with GlaxoSmithKline (GSK) to further develop PD-1 targeting therapies that may be effective in the treatment of cancer and other diseases. GSK will obtain exclusive worldwide rights to AMP-224 as well as other potential next generation fusion proteins that target PD-1.
› Verified 1 days ago
NPI Number | 1922406230 |
Type | Community/Retail Pharmacy |
Address | 2105 E Fire Tower Rd, Greenville, NC 27858 |
Phone Number | 252-321-6582 |
News Archive
Lab21 Limited, the global specialist in personalized medicine and clinical diagnostics, today announces the completion of a worldwide license from Cooperative Diagnostics to use its suite of patents and expertise for the development of its growing pipeline of molecular diagnostic kits. Financial details of the agreement were not disclosed.
"The links between climate, hunger and poor nutrition are becoming increasingly clear: a recent report for the Committee on World Food Security warned that climate change could significantly change the amount and quality of food consumed - with potentially devastating consequences for those most at risk of hunger," Irish Deputy Prime Minister Eamon Gilmore; Mary Robinson, president of the Mary Robinson Foundation Climate Justice; Ertharin Cousin, executive director of the World Food Programme; and Frank Rijsberman, CEO of the CGIAR Consortium, write in the CGIAR blog.
A new barcode chip developed by a multi-institutional team of investigators promises to revolutionize diagnostic medical testing. In less than 10 minutes and using just a pinprick's worth of blood, the chip can measure the concentrations of dozens of proteins, including those that herald the presence of diseases such as cancer and heart disease.
Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.
Amplimmune, Inc. today announced that it has entered into a broad strategic alliance with GlaxoSmithKline (GSK) to further develop PD-1 targeting therapies that may be effective in the treatment of cancer and other diseases. GSK will obtain exclusive worldwide rights to AMP-224 as well as other potential next generation fusion proteins that target PD-1.
› Verified 1 days ago
News Archive
Lab21 Limited, the global specialist in personalized medicine and clinical diagnostics, today announces the completion of a worldwide license from Cooperative Diagnostics to use its suite of patents and expertise for the development of its growing pipeline of molecular diagnostic kits. Financial details of the agreement were not disclosed.
"The links between climate, hunger and poor nutrition are becoming increasingly clear: a recent report for the Committee on World Food Security warned that climate change could significantly change the amount and quality of food consumed - with potentially devastating consequences for those most at risk of hunger," Irish Deputy Prime Minister Eamon Gilmore; Mary Robinson, president of the Mary Robinson Foundation Climate Justice; Ertharin Cousin, executive director of the World Food Programme; and Frank Rijsberman, CEO of the CGIAR Consortium, write in the CGIAR blog.
A new barcode chip developed by a multi-institutional team of investigators promises to revolutionize diagnostic medical testing. In less than 10 minutes and using just a pinprick's worth of blood, the chip can measure the concentrations of dozens of proteins, including those that herald the presence of diseases such as cancer and heart disease.
Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.
Amplimmune, Inc. today announced that it has entered into a broad strategic alliance with GlaxoSmithKline (GSK) to further develop PD-1 targeting therapies that may be effective in the treatment of cancer and other diseases. GSK will obtain exclusive worldwide rights to AMP-224 as well as other potential next generation fusion proteins that target PD-1.
› Verified 1 days ago
A.o.p. Inc. Type: Durable Medical Equipment & Medical Supplies Supplier Location: 835 Johns Hopkins Dr, Greenville, North Carolina 27834 Phone: (252) 752-7422 | |
Advanced Regenerative Care, Pllc Type: Medicare Supplier Location: 504 Red Banks Rd, Greenville, North Carolina 27858 Phone: (252) 321-3579 | |
Apria Healthcare Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1824 Progress Rd, Greenville, North Carolina 27834 Phone: (252) 757-1727 | |
Carolina Home Medical, Inc Type: DME Supplier - Oxygen Equipment & Supplies Location: 1913 East Firetower Road, Greenville, North Carolina 27858 Phone: (252) 758-9887 | |
Carolina Vision Care Type: Medicare Supplier Location: 1804w Arlington Blvd, Greenville, North Carolina 27834 Phone: (252) 752-4380 |